Today's Rundown Allergan pays Exicure $25M to discover nucleic acid hair loss drugs Bayer, Dewpoint take aim at heart disease, women's health in deal worth up to $100M VistaGen fails phase 2 depression trial, sparking stock rout Avidity nets $100M to bankroll antibody-oligonucleotide conjugates for muscle disorders ATAI Life Sciences, Cyclica team up for mental health JV Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy Thermo Fisher looks to buy fellow diagnostics maker Qiagen: Bloomberg Longtime Abbott chief Miles White, designer of AbbVie spinoff, bows out of CEO job Featured Story | | | Thursday, November 14, 2019 Allergan has teamed up with Exicure to discover treatments for hair loss disorders. Exicure is set to receive $25 million upfront to apply its spherical nucleic acid technology to two collaborative programs. |
|
|---|
|
Top Stories Thursday, November 14, 2019 Dewpoint Therapeutics, the biotech working to drug biomolecular condensates, has struck its first big deal. It’s teaming up with Bayer on new treatments for a pair of neglected fields: heart disease and women’s health. Thursday, November 14, 2019 A phase 2 trial of VistaGen Therapeutics’ AV-101 in major depressive disorder has missed its primary endpoint, sending shares in the nanocap biotech down 64% premarket. VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps. Wednesday, November 13, 2019 Avidity Biosciences is on a roll—this year, the company inked a $35 million research deal with Eli Lilly and hired on a new CEO, Sarah Boyce. Now, it's reeling in $100 million in its series C round as it works on its lead antibody-oligonucleotide program in myotonic dystrophy. Thursday, November 14, 2019 Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new joint venture aimed at battling mental health. Thursday, November 14, 2019 Backed by promising results from a small clinical study, Stanford University scientists are investigating the potential for treating peanut allergy with one injection of AnaptysBio’s anti-IL-33 etokimab, a drug that recently suffered a trial setback in eczema. Thursday, November 14, 2019 Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, which has the potential to become one of its largest acquisitions, according to a report from Bloomberg. Wednesday, November 13, 2019 Abbott Laboratories chief Miles White will shed his CEO title next year after a 21-year run at the company's helm—and several major transformations to his credit. Taking his place will be Robert Ford, whom White elevated to president and chief operating offer a year ago. Enrollment Showcase Resources Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation A Rare Affair for Rare Diseases January 12, 2020 | San Francisco, CA | 